The previous utilization of PSMA expression in the radionuclide treatment of prostate cancer, as well as the first published observations regarding the presence of this antigen on breast cancer cells, encourage similar clinical studies concerning the therapy of breast cancer in the future. This evidence concerns the gene FOLH1 and prostate cancer.